Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hypoglycemic Agents and Gut Microbiota in T2DM
NCT04287387Phase 4
Key facts
- Status
- Unknown
- Start
- Mar 2020
- Primary completion
- Mar 2021
- Countries
- 1
- Sponsor
- Peking Union Medical College Hospital
- Modality
- Orthosteric Ligands
- Conditions
- type 2 diabetes mellitus (T2DM)
01
Overview
Phase 4, open-label trial of liquid metformin (Aspargo Labs), acarbose, sitagliptin, dapagliflozin, pioglitazone and 1 more in type 2 diabetes mellitus (T2DM), sponsored by Peking Union Medical College Hospital. Status: unknown.
02
Design
- Study design
- Non-randomizedOpen-label
03
Registry description
Intestinal microflora refers to the trillions of microorganisms living in our gut, which is considered as an independent endocrine organ of human body. Intestinal microbiota plays a very important role in human health. The composition of human intestinal microbiota is affected by a variety of factors, including age, living region, eating habits, nutrition, probiotics, antibiotics and so on. It is found that the imbalance of intestinal microbiota is closely related to the occurrence and development of metabolic diseases including type 2 diabetes mellitus (T2DM). There are great differences in…
Beyond the preview
Go deeper on NCT04287387.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04287387.